Source comparison
CJC-1295 with DAC vs No DAC — Key Structural Differences
A 2010 study published in the Journal of Clinical Endocrinology and Metabolism found that CJC-1295 with DAC produced sustained growth hormone (GH) elevation for 6–13 days following a single subcutaneous injection. A duration that modified GRF 1-29 (CJC-1295 wi
This comparison does not assign a generated winner or score.
- A 2010 study published in the Journal of Clinical Endocrinology and Metabolism found that CJC-1295 with DAC produced sustained growth hormone (GH) elevation for 6–13 days following a single subcutaneous injection. A duration that modified GRF 1-29 (CJC-1295 without DAC) cannot achieve. The difference comes down to a single structural modification: the Drug Affinity Complex (DAC) is a synthetic linker molecule attached to the peptide backbone that binds to serum albumin, dramatically extending plasma half-life from approximately 30 minutes to over 8 days. That's not a minor adjustment. It changes how the compound is dosed, how it affects endogenous GH pulsatility, and what applications it's best suited for.
- We've worked with research institutions comparing both forms across physiological models. The version you select depends entirely on whether your protocol prioritizes sustained baseline GH elevation or preservation of natural pulsatile secretion patterns.
- Is CJC-1295 with DAC the same as CJC-1295 without DAC?
- No. CJC-1295 with DAC and CJC-1295 without DAC (modified GRF 1-29) are structurally and pharmacokinetically distinct peptides. The DAC modification extends half-life from 30 minutes to over 8 days, enabling sustained GH release for up to two weeks from a single dose, while the non-DAC version mimics natural pulsatile GH secretion with a peak at 30 minutes post-injection. The structural difference determines dosing frequency, plasma kinetics, and research applications.
- The confusion stems from nomenclature overlap. Both peptides derive from the same base sequence (growth hormone-releasing hormone analogue, amino acids 1-29), but only one carries the DAC linker. Researchers often shorten 'CJC-1295 without DAC' to 'CJC-1295' in casual reference, creating the false impression they're identical compounds. They're not. This article covers the exact structural modification that separates them, how DAC binding to albumin alters plasma kinetics, what dosing protocols each version requires, and which peptide fits protocols prioritizing pulsatile versus sustained GH elevation.